← Eichor
Study identifier: NCT07161882 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

ALG-LungCancerRegistry (SAFRO2202)

Condition: Lung Neoplasms · Carcinoma, Non-Small-Cell Lung · Carcinoma, Small Cell  ·  Sponsor: Société Algérienne de Formation et de Recherche en Oncologie

PhaseN/A
Planned participants3750
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

SAFRO 2202 ALG-Lung Cancer Registry is a prospective, multicenter, non-interventional observational study conducted across 21 public and university hospitals in Algeria. The objective is to characterize the epidemiological, clinical, pathological, molecular, and therapeutic features of patients diagnosed with lung cancer, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and carcinoid tumors. Eligible participants are adults aged 18 years or older, diagnosed at the time of inclusion or within the previous 12 months, and fully managed in oncology or pulmonology departments. Data are collected during routine clinical care and recorded in a secure electronic case report form (eCRF). No protocol-mandated interventions or study-specific visits are required. The study plans to enroll approximately 1,500 patients per year over a 30-month period. Primary outcomes include demographic and clinical profiles, tumor histology, molecular markers, staging at diagnosis, and treatment strategies (surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy). Secondary outcomes include treatment-related toxicities, objective response rate (ORR), progression-free survival (PFS), time to treatment discontinuation (TTD), and overall survival (OS). The findings from this registry will provide real-world evidence to support national health planning, improve lung cancer management, and guide future clinical and public health initiatives in Algeria.

This description comes directly from the study's public registry record.

Talk to the study team

Louisa ISSIAKHEM LOUNICI, CEO  ·  +213 770 48 43 36  ·  l.issiakhem@cmsolutionsdz.com

Always discuss trial participation with your own doctor first.

Locations (21)

Centre Pierre et Marie CurieAlgiers, Algiers Province, AlgeriaRecruiting
Chu Beni Messous - Isaad HassaniAlgiers, Algiers Province, AlgeriaRecruiting
CHU Mohamed Lamine Debaghine - Bab-el-OuedAlgiers, Algiers Province, AlgeriaRecruiting
Chu-Beni Messous - Isaad HassaniAlgiers, Algiers Province, AlgeriaRecruiting
EPH RouibaAlgiers, Algiers Province, AlgeriaRecruiting
CLCC AnnabaAnnaba, Annaba, AlgeriaRecruiting
CLCC BatnaBatna City, Batna, AlgeriaRecruiting
CAC-CHU Frantz FanonBlida, Blida Province, AlgeriaRecruiting
CHU- Hôpital Khelil AmraneBéjaïa, Béjaia Province, AlgeriaRecruiting
CHU Dr Abdesselam BenbadisConstantine, Constantine Province, AlgeriaRecruiting
EH Didouche MouradConstantine, Constantine Province, AlgeriaRecruiting
CLCC Draâ Ben KheddaTizi Ouzou, Draâ Ben Khedda, AlgeriaRecruiting

+ 9 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07161882